Gilead To File Truvada For HIV Prevention In EU In Early 2016
This article was originally published in Scrip
Executive Summary
Gilead Sciences has confirmed that it is preparing a regulatory filing in Europe for its HIV drug Truvada (emtricitabine and tenofovir disoproxil fumarate ) for pre-exposure prophylaxis (PrEP), and that a submission is expected sometime in the first quarter of 2016.